{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=57",
    "query": {
      "condition": "Phase 2 Study",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 17274,
    "total_pages": 1728,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=58&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=56&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T14:30:50.332Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03693625",
      "title": "A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urticaria"
      ],
      "interventions": [
        {
          "name": "GDC-0853",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 31,
      "start_date": "2018-09-27",
      "completion_date": "2019-10-23",
      "has_results": true,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03693625"
    },
    {
      "nct_id": "NCT01720225",
      "title": "Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2012-11-06",
      "completion_date": "2020-01-08",
      "has_results": true,
      "last_update_posted_date": "2020-12-24",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01720225"
    },
    {
      "nct_id": "NCT00504140",
      "title": "Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Interferon Alpha",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "5 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "1996-11",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2012-08-02",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00504140"
    },
    {
      "nct_id": "NCT02413489",
      "title": "An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Mantle-Cell",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Follicular"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2015-09-02",
      "completion_date": "2017-06-01",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Fountain Valley, California • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02413489"
    },
    {
      "nct_id": "NCT02318368",
      "title": "A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ficlatuzumab",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2014-11",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 13,
      "location_summary": "Fresno, California • Redondo Beach, California • Boca Raton, Florida + 9 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02318368"
    },
    {
      "nct_id": "NCT04221893",
      "title": "Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage IV Esophageal Adenocarcinoma",
        "Stage IV Esophageal Squamous Cell Carcinoma",
        "Stage IV Gastric Cancer",
        "Stage IV Adenocarcinoma of the Gastroesophageal Junction",
        "Stage IVA Esophageal Adenocarcinoma",
        "Stage IVA Esophageal Squamous Cell Carcinoma",
        "Stage IVA Gastric Cancer",
        "Stage IVA Adenocarcinoma of the Gastroesophageal Junction",
        "Stage IVB Esophageal Adenocarcinoma",
        "Stage IVB Esophageal Squamous Cell Carcinoma",
        "Stage IVB Gastric Cancer",
        "Stage IVB Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Anal Canal Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Esophageal Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Malignant Digestive System Neoplasm",
        "Metastatic Small Intestinal Carcinoma",
        "Pancreatobiliary Carcinoma",
        "Pathologic Stage IV Gastric Cancer AJCC v8",
        "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8",
        "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8",
        "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Stage IV Anal Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy (RT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2020-08-07",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Walnut Creek, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04221893"
    },
    {
      "nct_id": "NCT00616421",
      "title": "Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Infections"
      ],
      "interventions": [
        {
          "name": "MenACWY-CRM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed meningococcal ACWY vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "2 Years to 10 Years"
      },
      "enrollment_count": 2907,
      "start_date": "2008-03",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2016-02-15",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 52,
      "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 39 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00616421"
    },
    {
      "nct_id": "NCT02932306",
      "title": "Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne"
      ],
      "interventions": [
        {
          "name": "IDP-121 Lotion",
          "type": "DRUG"
        },
        {
          "name": "IDP-121 Vehicle Lotion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 820,
      "start_date": "2015-11-03",
      "completion_date": "2017-02-22",
      "has_results": true,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 39,
      "location_summary": "Guntersville, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 34 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Manhattan Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02932306"
    },
    {
      "nct_id": "NCT06806033",
      "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2025-03-05",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 33,
      "location_summary": "Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06806033"
    },
    {
      "nct_id": "NCT00140855",
      "title": "A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Synovial Sarcoma"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2005-06-08",
      "completion_date": "2007-07-01",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-10-30T14:30:50.332Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00140855"
    }
  ]
}